Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E T Hawk

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Gut|October 23, 2003
Aspirin: still learning about the wonder drugE T Hawk, J L Viner
Hematology/Oncology Clinics of North America|August 19, 2000
Primary cancer prevention trialsE T Hawk, S M Lippman
Annals of Internal Medicine|February 15, 2001
Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and researchE T Hawk, J L Viner
Annals of the New York Academy of Sciences|January 25, 2002
The future of colon cancer preventionA Umar, J L Viner, E T Hawk
Gastroenterology|September 14, 2004
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposisRussell F Jacoby, Carolyn E Cole, E T Hawk, et al.
Oncology (Williston Park, N.Y.)|May 29, 2000
Adenocarcinoma of the esophagus: risk factors and preventionE I Heath, P J Limburg, E T Hawk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2000
National Cancer Institute--supported cancer chemoprevention research: coming of ageW McCaskill-Stevens, E T Hawk, P J Flynn, et al.
Clinical Chemistry|February 25, 1998
Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoringR Lieberman, J A Crowell, E T Hawk, et al.
Carcinogenesis|July 1, 1996
Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladderK V Rao, C J Detrisac, V E Steele, et al.
IARC Scientific Publications|February 28, 2001
Surrogate end-point biomarkers in chemopreventive drug developmentG J Kelloff, C C Sigman, E T Hawk, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Gut|October 23, 2003
Aspirin: still learning about the wonder drugE T Hawk, J L Viner
Hematology/Oncology Clinics of North America|August 19, 2000
Primary cancer prevention trialsE T Hawk, S M Lippman
Annals of Internal Medicine|February 15, 2001
Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and researchE T Hawk, J L Viner
Annals of the New York Academy of Sciences|January 25, 2002
The future of colon cancer preventionA Umar, J L Viner, E T Hawk
Gastroenterology|September 14, 2004
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposisRussell F Jacoby, Carolyn E Cole, E T Hawk, et al.
Oncology (Williston Park, N.Y.)|May 29, 2000
Adenocarcinoma of the esophagus: risk factors and preventionE I Heath, P J Limburg, E T Hawk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2000
National Cancer Institute--supported cancer chemoprevention research: coming of ageW McCaskill-Stevens, E T Hawk, P J Flynn, et al.
Clinical Chemistry|February 25, 1998
Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoringR Lieberman, J A Crowell, E T Hawk, et al.
Carcinogenesis|July 1, 1996
Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladderK V Rao, C J Detrisac, V E Steele, et al.
IARC Scientific Publications|February 28, 2001
Surrogate end-point biomarkers in chemopreventive drug developmentG J Kelloff, C C Sigman, E T Hawk, et al.
Pageof 3